TGD001 is a fusion protein with a vWF binding moeity linked to the catalytic domain of Urokinase. Once TGD001 binds to vWF present in all blood clots it will localy activate Plasminogen into Plasmin and Plasmin is known to cleave fibrin (tPA is a commercial available product that works with the same Mode of Action but has, due to the systemic impact, a lot of side effects and poor effictivity) but in the last few years it has been scientifically proven that plasmin can also cleave vWF when it is in the close proximity of vWF. TGD001 is capable to show this in pre-clinical models both in AIS and iTTP. TGD001 can be given as a bolus injection in one dose with fast onset of the Mode of Action (in vitro shown that TGD001 works within 5 minutes).